Navigation Links
New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders

d interferon and ribavirin. Only 7 of the 57 patients entering the study dropped out prior to week 12.

Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as certain technical and laboratory support and other services for MIGENIX's celgosivir Phase II combination study in chronic HCV patients and a related extension protocol. In addition, the Agreement granted Schering limited periods of exclusivity for data review of clinical trial results and for the negotiation of a license agreement. With the new top-line results, we will be working to provide a data package to Schering over the next few weeks, after which Schering's limited period of exclusivity for data review under the Agreement will commence. No license terms have been negotiated with Schering to date.

Celgosivir is an alpha-glucosidase I inhibitor and is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore has the potential to be included as part of many combination therapeutic approaches to improve efficacy in anti-HCV therapy.

HCV, the most common chronic blood-borne infection in the United States, causes inflammation of the liver and may progress to more serious complications such as cirrhosis of the liver, liver cancer and death. Approximately 2.7 million people in the United States are chronically infected with HCV, and the Centers for Disease Control and Prevention (CDC) estimates that by the year 2010, the number of deaths attributed annually to HCV could surpass that due to HIV/AIDS in the US. Worldwide, the World Health Organ
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:9/16/2014)... report analyzes the worldwide markets for Digital Radiography in US$ ... the US, Canada , Japan ... , Middle East , ... and forecasts are provided for the period 2013 through 2020. ... Market data and analytics are derived from primary and secondary ...
(Date:9/16/2014)... 16, 2014 Adaptive Biotechnologies, a clinical stage ... profile the adaptive immune system, is pleased to announce ... Commercial Officer (CCO). The addition of Brain to the ... from leading global healthcare companies, including Dean Schorno ... from Genomic Health and Sean Nolan (CTO) ...
(Date:9/16/2014)... 16, 2014 QPID Health , a leader ... headquarters in Boston and their first ... be at 175 Franklin Street in Boston ... QPID Health,s new Southern California office ... expansion will help meet the demands of customers nationwide.  Both ...
Breaking Medicine Technology:Global Digital Radiography Industry 2Global Digital Radiography Industry 3Global Digital Radiography Industry 4Global Digital Radiography Industry 5Global Digital Radiography Industry 6Global Digital Radiography Industry 7Global Digital Radiography Industry 8Global Digital Radiography Industry 9Global Digital Radiography Industry 10Global Digital Radiography Industry 11Global Digital Radiography Industry 12Global Digital Radiography Industry 13Global Digital Radiography Industry 14Global Digital Radiography Industry 15Global Digital Radiography Industry 16Global Digital Radiography Industry 17Global Digital Radiography Industry 18Global Digital Radiography Industry 19Global Digital Radiography Industry 20Global Digital Radiography Industry 21Global Digital Radiography Industry 22Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... GlaxoSmithKline (GSK) is committed to ensuring that consumers and ... alli is safe and effective when used as directed. ... locally in the gastro-intestinal tract. GSK continues to proactively ... relevant information with regulatory agencies. Since orlistat ...
... FORD, Pa., April 14, 2011 Endo Pharmaceuticals (Nasdaq: ... results on April 28, 2011 and will host a conference ... discuss these results.   David P. Holveck, president ... executive vice president of R&D, Alan Levin, executive vice president ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce First Quarter 2011 Financial Results on April 28, 2011 2
(Date:9/16/2014)... Kathleen Doheny HealthDay Reporter ... urine test can routinely spot human papillomavirus (HPV), which is ... found. "Our study shows that testing urine for HPV ... the cervix for HPV," said lead researcher Dr. Neha Pathak. ... fellow at Queen Mary University of London, England. The ...
(Date:9/16/2014)... 2014 These new programs allow those who ... receive up to $10,000 in a 0% interest free, 2nd ... other state and federal programs, are listed on their private ... until you sell or move out of the property. The ... loan. There are no monthly payments paid by the Borrower. ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... Washington, DC (PRWEB) September 16, 2014 ... could potentially yield hundreds of billions of dollars in ... 2007 report by the Commonwealth Fund. To help spur ... is seeking up to 10 collaborative groups from across ... 1.0 ( http://bit.ly/1wo4gsa ) - a handbook designed ...
(Date:9/16/2014)... Angeles, CA (PRWEB) September 16, 2014 ... League of United Latin American Citizens (LULAC) will host ... LULAC’s Feria de Salud will feature free health screenings ... Other free testing includes glucose and cholesterol levels as ... will be available for children under 6 years old ...
Breaking Medicine News(10 mins):Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2
... ... is giving away 10,000 free business card pens. , ... (PRWEB) December 2, 2009 -- National Pen ( www.pens.com ), a ... pens. , , , , ,“We have a new way to promote business that no ...
... ... direct microwave signal transmissions away from users will be available in early 2010 from ... ... signal transmissions away from users will be available in early 2010 from Aerius International ...
... ... and walkers from Las Vegas and around the country will cross the ... by Zappos.com, raising over $3.2 million for the Crohn,s & Colitis Foundation ... charity of the race, the funds will go toward research, education, and ...
... 2 The American Health Information Management Association,s Board ... be the next chief executive of the 55,000-member health ... information experience includes academia, systems management, strategic expertise, governance ... scheduled to take office January 13, 2010. , "Dr. ...
... , , WASHINGTON, Dec. ... 2 in their campaign against the U.S. House bill,s pro-life ... CEO Charmaine Yoest released this statement in response to the ... "By confusing abortion with health care, the feminist groups and ...
... Washington Post Highlights Dangers , WASHINGTON, ... way, many medical treatments and preventative measures we take for granted may ... to bear on the debate over healthcare reform has been widely reported. ... likely impact if that pressure to influence healthcare policy is not curtailed. ...
Cached Medicine News:Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
... system has been designed to enhance fixation ... cluster hole configurations. The objective of the ... three primary modes: Tilt, migration and rotation. ... in initial and long-term fixation. The porous ...
Optimal solution for normal acetabulum and younger patients....
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
Medicine Products: